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ABSTRACT 
 
OBJECTIVE-We tested the primary hypotheses that sphingolipid and diacylglycerol (DAG) 
content is higher within insulin resistant muscle and that the association between 
intramyocellular triglycerides (IMTG) and insulin resistance is muscle fiber type-specific. 
RESEARCH DESIGN AND METHODS-A nested case-control analysis was conducted in 22 
obese (BMI >30 kg/m2) women who were classified as insulin resistant (IR; n = 12) or insulin 
sensitive (IS; n = 10), determined by hyperinsulinemic euglycemic clamp (>30% greater in IS 
compared to IR, P <0.01). Sphinoglipid and DAG content was determined by HPLC/MS/MS. 
Fiber type-specific IMTG content was histologically determined. Gene expression was 
determined by qPCR. RESULTS-Total (555±53 vs. 293±54 pMol/mg protein, P =0.004), 
saturated (361±29 vs. 179±34 pMol/mg protein, P =0.001) and unsaturated (198±29 vs. 113±66 
pMol/mg protein, P =0.034) ceramides were higher in IR compared to IS. DAG concentrations, 
however, were similar. IMTG content within type I myocytes, but not type II myocytes, was 
higher in IR compared to IS (P =0.005). Insulin sensitivity was negatively correlated with IMTG 
within type I myocytes (R = -0.51, P =0.026), but not with IMTG within type II myocytes. The 
proportion of type I myocytes was lower (41% vs. 59%, P <0.01) in IR. Several genes involved 
in lipid droplet and fatty acid metabolism were differentially expressed in IR compared to IS. 
CONCLUSIONS-Human skeletal muscle insulin resistance is related to greater IMTG content 
in type I, but not type II myocytes, to greater ceramide content, and to alterations in gene 
expression associated with lipid metabolism.  
 
 
 
Skeletal muscle insulin resistance is a key factor in the development of type 2 diabetes 
mellitus (T2DM), although the exact mechanisms that underlie insulin resistance in humans 
remain elusive. Considerable efforts have been made in the past several decades to better 
understand the role of impaired fatty acid metabolism in skeletal muscle insulin resistance (1, 2). 
Many earlier studies, both in animal models (3) and in humans (4, 5) indicated that 
intramyocellular triglyceride (IMTG) accumulation was associated with insulin resistance, 
thereby providing a potential link between dysregulated fatty acid metabolism and insulin 
resistance. However, it has become increasingly apparent that IMTG do not directly confer 
insulin resistance but rather, under certain circumstances, likely provide a surrogate for other 
bioactive lipid metabolites within muscle such as sphingolipids (including ceramide) and 
diacylglycerol (DAG) (4, 6).   
Studies in animal and cell culture models indicate that sphingolipids and DAG can be key 
mediators of insulin resistance (7-9). However, a recent study of acute hyperlipidemia in rodents 
indicates that ceramide and DAG content are not associated with muscle insulin resistance (10). 
Furthermore, studies conducted in humans do not provide a firm consensus as to whether 
ceramides or DAGs are associated with muscle insulin resistance (11). Some studies indicate that 
muscle ceramide content is elevated in obese compared to lean individuals (12, 13), or that 
increases in muscle ceramide content as a result of lipid infusion (15), or conjugated linoleic acid 
supplementation (16), were associated with decreased insulin sensitivity. Endurance training in 
obese subjects reduced muscle ceramide content with a concomitant improvement in insulin 
sensitivity (17, 18). In contrast, a recent study by Skovbro et al. found that total muscle ceramide 
content was similar in subjects despite a wide range of insulin sensitivity (19). Also refuting a 
role for ceramide in human muscle insulin resistance, Itani et al., reported that lipid-induced 
insulin resistance did not alter ceramide content (14).  
The role of muscle DAG content in insulin resistance is also unclear. Muscle DAG 
content has been shown to be elevated in obese and T2DM subjects (20) and increased following 
a 6-hr lipid infusion which reduced insulin sensitivity (14). In contrast, IMTG, but not DAG 
content in muscle, was reported to be elevated in obese diabetic compared to obese nondiabetic 
subjects (21).  Therefore, in order to help address the controversy in the literature surrounding 
the role for specific lipid metabolites in insulin resistance, we conducted comprehensive mass 
spectrometry-based DAG and sphingolipid profiling in human muscle insulin resistance while 
accounting for factors well known to influence insulin sensitivity, namely obesity and physical 
activity.  
Quantification of intramyocellular lipids in humans is further complicated by a 
heterogenous myocyte or fiber composition. Type I myocytes have a greater capacity for 
oxidative phosphorylation (22, 23), and typically can contain two-to-three times more IMTG 
than type II myocytes (22, 24, 25). Furthermore, type I myocytes have been reported to be more 
insulin sensitive than type II (26, 27). However, it is not clear, insulin sensitivity is related to 
differences in myocyte specific IMTG content, nor is it known whether sphingolipid or DAG 
content is related to muscle cell type. We tested the primary hypotheses that sphingolipid and 
DAG content is higher within insulin resistant muscle and that type I myocyte IMTG content is 
specifically related to insulin resistance. We also explored whether differences in the expression 
of several genes related to lipid metabolism could play a role in insulin resistance associated with 
IMTG accumulation.  
 
RESEARCH DESIGN AND METHODS 
Study population. Subjects for this nested case-controlled study were selected from ongoing 
clinical investigations of skeletal muscle insulin resistance. Only female subjects were included 
to provide a gender-controlled analysis. Women aged 60–75 yrs were recruited though 
advertisements in the Pittsburgh, PA area. A brief phone screening initially determined eligibility 
for study participation. Potential subjects who were determined to be sedentary (exercise ≤1 
day/wk), weight stable (±3kg in the previous 6mo), with a body mass index (BMI) >30 kg/m2, 
and nonsmokers were further evaluated at the Clinical Translational Research Center (CTRC) at 
the University of Pittsburgh. Exclusionary criteria included uncontrolled hypertension (>150/95 
mmHg), anemia (Hct<34%), elevated liver enzymes (25% above normal), proteinuria, or 
hypothyroidism (sensitive TSH 8mIU/l). Potential subjects were also excluded if they reported 
taking chronic medications known to affect glucose homeostasis. Following the medical 
screening, potential subjects then completed a 2-h, 75-g oral glucose tolerance test (OGTT) to 
determine glucose tolerance status. Subjects with T2DM determined by fasting glucose 
>126mg/dl were excluded. All subjects gave written consent to the protocol, which was 
approved by the University of Pittsburgh’s Institutional Review Board. 
 
Insulin sensitivity. Insulin sensitivity was determined by a 4-hr hyperinsulinemic (40 
mU/m2/min) euglycemic clamp and [6,6-2H2] glucose infusion as previously described (28). 
Briefly, subjects reported to the CTRC the evening prior to the clamp and following a 48-hr 
period in which they refrained from any vigorous physical activity. A continuous intra venous 
infusion of insulin (Humulin; Eli Lilly, IN) was begun at ~7AM, and euglycemia (target 
90mg/dl) was maintained using an adjustable infusion of 20% dextrose. To measure rate of 
insulin stimulated glucose disposal and residual endogenous glucose production (EGP), a primed 
(0.22 µmol/kg), continuous (17.6 µmol/kg/min) infusion of [6,6-2H2] glucose was administered 
(29). [6,6-2H2] glucose enrichment in plasma was determined by gas chromatography/mass 
spectrometry (6890 Network/5973 Series; Agilent, Santa Clara, CA) as previously described 
(30). Plasma glucose was measured by the glucose-oxidase method (2300 Stat Plus; Yellow 
Springs Instruments, Yellow Springs, OH). Fasting plasma insulin concentration was determined 
by an enzyme linked immunosorbent assay (Millipore, Billerica, MA). Rate of glucose disposal 
(Rd) was calculated using the tracer: tracee method with a modified version of the Steele et al., 
equation (31) 
  
Muscle biopsy. Percutaneous muscle biopsy samples were obtained in the fasted state prior to 
the glucose clamp, as described previously (32). Briefly, muscle biopsies were obtained from the 
vastus lateralis, 15cm above the patella. A portion of the specimen (~30mg) was snap frozen in 
liquid nitrogen and stored at -80°C for sphingolipid and diacylglycerol analysis. A second 
portion (~20mg) was snap frozen and stored at -80°C for gene expression analysis. A third 
portion of the specimen for histochemistry was mounted on a small piece of cork with mounting 
medium (Shandon Cryochrome; Thermo Electron, Pittsburgh, PA), frozen in isopentane cooled 
with liquid nitrogen for 2–3 min (-160°C), and then placed into liquid nitrogen. All samples were 
stored at -80°C until analysis. 
 
Analysis of sphingolipid and diacylglycerol species. Briefly, liquid nitrogen-frozen samples 
(~30mg) were homogenized in ice-cold buffer (250mM sucrose, 25mM KCl, 50mM Tris, and 
0.5mM EDTA, pH 7.4). Total content as well as the various molecular species of diacylglycerol 
and sphingolipid were measured by high-performance liquid chromatography-tandem mass 
spectrometry as previously described in detail (33).  
 
Analysis of non-esterified plasma free fatty acids. Plasma free fatty acid concentrations were 
determined by gas chromatography with flame ionization detection (6890N; Agilent, Santa 
Clara, CA) using heptanoic acid as an internal standard. Free fatty acids were derivatized with 
dimethylamine using Deoxo-Fluor reagent (Sigma-Aldrich, St. Louis, MO). 
 
Histochemical analysis for fiber type and IMTG content. Histochemical analysis was 
performed on serial sections using a modified version of methods previously used in our 
laboratory (32). Briefly, mounted biopsy samples were sectioned (10µm) on a cryostat 
(Cryotome E; Thermo Shandon, Pittsburgh, PA) at -20°C and placed on a glass slide. Sections 
were then stained in a filtered solution of Oil Red O (300mg/ml in 36% triethylphosphate) for 30 
minutes at room temperature. Thereafter, sections were incubated with primary antibodies for 
anti-human myosin heavy chain (MYH)7 (type I myocytes) and MYH2 (type IIa myocytes) 
overnight at room temperature and subsequently incubated with fluorescein (FITC) (type IIa 
myocytes) and Rhodamine (type I myocytes) conjugated secondary antibodies (Santa Cruz 
Biotechnologies, Santa Cruz, CA). Type IIx fibers remained unstained. Images were visualized 
using a Leica microscope (Leica DM 4000B; Leica Microsystems, Bannockburn, IL), digitally 
captured (Retiga 2000R camera; Q Imaging, Surrey, Canada), and analyzed using specialized 
software (Northern Eclipse, v6.0; Empix Imaging, Cheektowaga, NY). Oil red O staining 
intensity and cross sectional area were determined in Type I and Type II myocytes. Analysis is 
based on ~200 fibers per section (range 130-350). 
 
Gene expression analysis. Gene expression analysis was carried out in a subset of subjects from 
each group, based on availability of vastus lateralis biopsy specimen (6 IR and 6 IS). Total RNA 
was isolated using Trizol reagent (Invitrogen; Carlsbad, CA). Isolated RNA was then further 
purified using a silicon-membrane spin column including an on-column DNase I treatment 
(Qiagen, Valencia, CA). Total RNA was reverse transcribed using Moloney Murine Leukemia 
Virus (MMLV) reverse transcriptase (SABiosciences, Frederick, MD). Gene expression was 
determined by quantitative real-time polymerase chain reaction (qRT-PCR) using SYBR green 
based custom RT2 Profiler PCR Arrays (SABiosciences, Frederick, MD). qRT-PCR was 
performed on an ABI prism 7900 (Applied Biosystems, Foster City, CA). Baseline Ct and 
threshold were determined and set for all samples. The relative level of mRNA expression for 
each gene in each sample was normalized to the average expression of β-2-microglobulin, 
hypoxanthine phosphoribosyltransferase (HPRT1), glyceraldehydes-3-phosphate dehydrogenase 
(GAPDH), and beta actin (ACTB), and expressed as 2-∆Ct. 
 
Body composition and peak aerobic capacity. Total body fat and lean mass were assessed 
using dual-energy X-ray absorptiometry (GE Lunar Prodigy and Encore 2005 software v9.3). 
Subjects performed a VO2 peak test on an electronically braked cycle ergometer to determine 
aerobic fitness (Sensor Medics, Yorba Linda, CA) as previously described (34).  
 
Statistical analysis. Group comparisons were made by an independent two-tailed Students t-test. 
Correlations between variables were determined by Person’s correlation co-efficient. All data are 
mean ± SEM unless otherwise stated. Statistical significance was set at P<0.05. 
 
RESULTS 
Subject characteristics. Ten insulin sensitive (IS) and 12 insulin resistant (IR) women were 
matched for age, body mass, BMI and physical fitness (VO2 peak) (Table 1). There was no 
significant group difference in fasting plasma glucose, insulin or free fatty acid levels. However, 
by design, Rd during the hyperinsulinemic euglycemic clamp was greater (P<0.01) in the IS 
when compared to the IR group (Table 1). 2-hr plasma glucose levels during the OGTT were 
also significantly higher in the IR group compared to the IS group (P =0.016). The IR (n=6) and 
IS (n=6) subgroups for gene expression analysis had similar characteristics as their respective 
groups overall (data not shown).  
 
Muscle fiber distribution. Type I and II myocyte content and myocyte average cross sectional 
area are presented in Table 2. The IS group had a higher proportion of type I myocytes (P 
=0.002) and a lower proportion of type IIa (P =0.014 and type IIx (P =0.02), than the IR group. 
When data from both groups were combined, there was a higher proportion of type IIa compared 
to type IIx myocytes (P =0.008). No differences were observed in myocyte average cross 
sectional area. With both groups combined, there was a significant positive correlation between 
the proportion of type I myocytes and insulin sensitivity and a negative correlation between the 
proportion of type II myocytes (type IIa and IIx combined) and insulin sensitivity (Table 3). 
 
Muscle content of sphingolipid and diacylglycerol. The data for muscle content of 
sphingolipid and diacylglycerol species is presented in Figure 1. We observed higher total levels 
of ceramide (555±53 vs. 293±34 pMol/mg protein, P =0.004), total unsaturated ceramide 
(198±29 vs. 114±21 pMol/mg protein, P =0.034), and total saturated ceramide (361±29 vs. 
179±34 pMol/mg protein, P =0.001) in the IR group, compared to the IS group. We also 
observed higher levels of specific ceramide species containing the following fatty acids; myristic 
(C14:0) (4.0±0.8 vs. 1.9±0.4 pMol/mg protein, P =0.044), palmitic (C16:0) (58±14 vs. 18±5 
pMol/mg protein, P =0.023), and stearic (C18:0) (72±10 vs. 40±7 pMol/mg protein, P =0.02) in 
IR compared to IS muscle. There also tended to be greater content of sphingolipids containing 
palmitoleic (C18:1) (43±11 vs. 19±3 pMol/mg protein, P =0.077) and lignoceric (C24:0) 
(201±25 vs. 123±29 pMol/mg protein, P =0.06) acids, and sphingosine (3.4±0.6 vs. 2.2±0.3 
pMol/mg protein, P =0.08) in IR muscle. When data were combined from both groups we 
observed a significant negative correlation between total unsaturated, total saturated, and total 
ceramide content and insulin sensitivity (Table 3). Total ceramide (R =0.517, P<0.05) and total 
saturated ceramide (R =0.523, P<0.05) were positively correlated with Type II myocyte 
percentage. However, no significant differences in total or individual diacylglycerol species were 
observed between IS and IR subjects.  
 
Myocyte-specific IMTG content. Type I and II myocyte-specific IMTG content are shown in 
Figure 2. Total muscle IMTG was greater in the IR group compared to the insulin sensitive 
group (P =0.009). Type I myocyte-specific IMTG content was also greater in the IR group 
compared to the IS group (P =0.005). There was no difference in type II myocyte-specific IMTG 
content between IS and IR groups, nor was IMTG content different in IR within subtypes of type 
IIa and type IIx myocytes. When both groups were combined we observed a significant negative 
correlation between type I myocyte IMTG content and insulin sensitivity whereas there was no 
relationship between insulin sensitivity and type II myocyte (type IIa and IIx combined) IMTG 
content (Figure 2). 
Muscle gene expression. The gene expression data for IR and IS sub-groups is presented in 
Figure 3. Expression levels of key genes, including facilitated glucose transporter member 4 
(GLUT4), insulin receptor substrate (IRS)1 and IRS2 were lower in IR, indicating insulin 
resistance in this group at the tissue level in accord with their insulin resistance assessed in vivo. 
The expression of genes relating to oxidative phosphorylation transcription factors, fatty acid 
metabolism, ceramide metabolism, and lipid droplet associated proteins were examined. We 
found lower expression of the transcription factors peroxisome proliferator-activated receptor 
(PPAR) α and PPARγ in the IR group compared to the IS group. Also, expression of PPARγ 
coactivator 1α (PGC-1α) and nuclear respiratory factor 1 (NRF1) tended to be lower in IR 
muscle. Furthermore, we observed a lower expression of carnitine palmitoyltransferase 1B 
(CPT1B) and malonyl-CoA decarboxylase (MLYCD), genes that are related to fatty acid 
metabolism. Gene expression of lipid droplet associated proteins hormone-sensitive lipase 
(HSL), adipose differentiation-related protein (ADRP), adipose triglyceride lipase (ATGL), and 
synaptosomal-associated protein 23 (SNAP23) was lower in the IR group compared to IS. 
Interestingly, the expression of genes relating to ceramide metabolism was not different between 
groups. The expression of tumor necrosis factor alpha (TNFα) tended to be higher in the IR 
group compared to the IS group (P =0.09).  
 
DISCUSSION 
Despite a preponderance of evidence from cell culture and animal models suggesting a 
role for both ceramide and diacylglycerol in skeletal muscle insulin resistance (7, 8), there is 
actually no consensus as to whether this is relevant to human insulin resistance (12-14, 16, 18). 
This study was conducted for three purposes: (a) to determine whether diacylglycerol or 
sphingolipid species are elevated in IR human skeletal muscle; (b) to investigate whether the 
associations between intramyocellular lipids are dependent on muscle fiber type; and (c) to 
explore whether the skeletal muscle expression of several key genes relating to lipid metabolism 
are altered in IR muscle corresponding to intramyocellular lipid content. 
A primary finding of our study was that total as well as saturated and unsaturated 
ceramide content was ~2-fold higher in IR skeletal muscle in human subjects independent of 
obesity, physical fitness and plasma free fatty acid concentration. These results extend the 
findings of Adams et al., who observed elevated ceramide content in skeletal muscle of obese 
subjects (13). Studies by Straczkowski et al., also found that ceramide accumulation in skeletal 
muscle was inversely related to insulin sensitivity (12, 15). They also suggested that higher 
ceramide content in lean offspring of patients with T2DM was due to decreased ceramide 
degradation, whereas IR of obesity was caused by an increase in de novo ceramide synthesis (12, 
15). Not all studies, however, have observed an association between muscle ceramide content 
and insulin resistance (14, 19). These discrepant results could be attributed to differences in the 
subject population studied, e.g. age, gender, physical activity, as well as methodological 
differences in assessing ceramide content and insulin sensitivity (11). Thus, provides important 
new information about the relationship between elevated ceramide content and muscle insulin 
resistance This is the first to comprehensive profile of the content of the various molecular 
species of ceramide in human IR muscle using tandem mass spectrometry while controlling for 
obesity, physical fitness and age. This is the first study to demonstrate elevated levels of both 
saturated and unsaturated ceramides, as well as specific ceramides containing C14:0, C16:0, and 
C18:0 fatty acids in IR human muscle. 
None of the prior studies examining ceramide in human muscle have accounted for 
heterogeneity in muscle type that could account for differences in insulin sensitivity. Our novel 
finding that ceramide content was associated with a higher percentage of type II myocytes 
suggests that ceramide accumulation may be fiber type dependent. Further investigation is 
needed to confirm this. In addition, the complementary observations that both the IMTG content 
in type I myocytes and the lower proportion of type I myocytes are related to insulin resistance 
provide insight into muscle heterogeneity in lipid metabolism in insulin resistance. These data 
suggest a possibility that type I myofibers may have a greater capacity to buffer increases in free 
fatty acids by partitioning to lipid droplet IMTG, whereas type II fibers have a reduced capacity 
to incorporate excess fatty acids into IMTG and are more inclined to partition to lipotoxic 
mediators such as ceramide species. An impairment of skeletal muscle oxidative capacity has 
been suggested to initiate or potentiate insulin resistance (35). Our data indicate that the 
proportion of type I and type II myocytes is associated with higher ceramide content and insulin 
resistance, and that the expression levels of several genes related to mitochondrial biogenesis and 
fatty acid metabolism are lower in insulin resistance. Therefore, our complementary results 
support the concept that a low oxidative capacity of muscle may be associated with ceramide 
accumulation and insulin resistance. This is consistent with previous reports that the increase in 
whole muscle IMTG content in obesity or T2DM is primarily due to increased IMTG in type I 
myocytes (25), and that differences in fiber type proportion also play a role in insulin resistance 
of obesity and T2DM (36, 37). These observations are supported by a number of reports 
suggesting that type I myocytes are more insulin responsive than type II myocytes (26, 27, 38). 
Yet, differences in fiber type proportion between obese subjects either with or without T2DM 
have been reported in some (36, 37), but not all previous studies (22, 24).  
 Despite evidence in IR animal models supporting a role for DAG in insulin resistance (8, 
9), we did not observe an increased level of DAG in insulin resistant muscle. Straczkowski et al. 
have also reported elevated levels of ceramide, but not DAG, in obese impaired glucose tolerant 
(IGT) versus obese normal glucose tolerant (NGT) subjects (12). A possible reason for lipid-
induced insulin resistance by ceramide and not DAG, and visa versa, may be higher levels of 
palmitate result in greater ceramide accumulation, while unsaturated fatty acids partition towards 
DAG (39). Thus both ceramides and DAG can potentially induce insulin resistance depending on 
the degree of saturation of the lipid overload. Our finding that C16:0 ceramide was more than 3-
fold higher in IR muscle is consistent with this. Thus it is plausible that basal levels of ceramide 
and DAG in muscle are influenced by the degree of saturation and palmitate content in the diet 
of obese individuals. Further studies are needed to address this attractive hypothesis. 
We also examined the differential expression of several other genes relating to lipid 
metabolism, which could underlie accumulation of IMTG and other bioactive species, i.e., DAG 
and ceramide. We found that many genes involved in ceramide synthesis and degradation were 
not differentially expressed in IR muscle with increased ceramide content. A recent report 
suggests that over expression of acid ceramidase prevents the inhibitory effect of saturated fatty 
acids on insulin signaling (40). Also, inhibition of serine palmitoyltranseferase in zucker diabetic 
fatty (ZDF) rats, by treatment with the amino acid antibiotic myriocin, prevented the onset of 
T2DM and inhibited an increase in ceramide content in muscle, when compared to non-treated 
ZDF rats (41).  Our results suggest that factors other than increased enzyme content, possibly 
increased enzyme activity or fatty acid flux, contribute to ceramide accumulation in IR muscle. 
In support of this, Straczkowski et al., demonstrated that the activity of neutral 
sphingomyelinase, the enzyme that converts sphingomyelin to ceramide, is increased in muscle 
of obese IGT compared to obese NGT, concomitant with higher ceramide content (12). Finally, 
the observation that gene expression of TNFα tended to be elevated in IR muscle, albeit 
statistically non-significant, concomitant with elevated ceramide content is consistent with data 
demonstrating that TNFα can stimulate de novo ceramide biosynthesis (42). 
To further characterize intramyocellular lipid content and metabolism in IR skeletal 
muscle, we determined the expression of selected genes coding for lipid droplet proteins and 
proteins involved in lipid droplet hydrolysis. ATGL and HSL expression/activity have been 
demonstrated to contribute to adipose tissue and skeletal muscle triacylglycerol lypolysis, 
elevated plasma fatty acid levels and accumulation of ectopic lipid deposits associated with 
T2DM (43). Our observation that ATGL and HSL mRNA are lower in IR muscle is in line with 
reports of lower expression of these lipases in obesity and/or insulin resistance (44, 45). We also 
found lower expression of ADRP in IR muscle. Consistent with this, Philips et al. showed that 
skeletal muscle protein expression of ADRP was up-regulated in response to improvements in 
insulin action induced by weight loss and insulin sensitizer pharmacotherapy (46). Furthermore, 
ATGL and ADRP have been reported to be more highly expressed in type I muscle fibers (47, 
48). The fiber type-specific expression of ATGL and ADRP, and our observation of reduced type 
I fibers in obese IR subjects, potentially explains the lower level of ATGL and ADRP observed 
in whole muscle in the present study. It is tempting to speculate the same may be true for other 
lipases, and that fiber type composition plays a greater role in insulin resistance that previously 
thought. Furthermore, the trend toward higher TNFα gene expression tended to be higher in IR 
muscle is in line with reports that TNFα represses ATGL expression (49). We also observed for 
the first time in human muscle that the expression of SNAP23, a member of the SNARE family 
of proteins whose function is to mediate intracellular vesicle fusion events including GLUT4 
transport to the plasma cell membrane and lipid droplet fusion (50), is lower in IR muscle. This 
novel finding potentially linking intramyocellular lipid droplets and glucose transport is 
supported by others describing an association between SNAP23 and fatty acid-induced insulin 
resistance (50). 
Future studies should be conducted to examine whether or not interventions such as 
exercise or weight loss affect oxidative capacity, DAG, ceramide and insulin sensitivity to better 
understand these associations in humans. Although we substantiated our insulin resistance 
phenotype with expression of key genes involved in insulin signaling and glucose transport, 
additional studies are needed to link intramyocellular lipids, fiber type, oxidative capacity and 
activation of specific insulin signaling proteins.  Taken together, however, these results suggest a 
role for muscle fiber type proportion and/or the oxidative capacity of muscle in insulin 
resistance, possibly through partitioning muscle lipids into either triglycerides or ceramides. 
In summary, ceramide but not diacylglycerol is elevated in IR human skeletal muscle 
independent of obesity, physical activity or aerobic fitness. Moreover, this study also indicates 
that muscle fiber type as well as fiber type-specific lipid content is associated with insulin 
resistance in muscle. Importantly, key genes associated with fatty acid metabolism and lipid 
droplet regulation are decreased in IR muscle. Together, these data suggest that mechanisms 
underlying the associations between intramyocellular lipids and insulin resistance likely involve 
ceramide, which in turn may be dependent on the muscle fiber type or its oxidative capacity. 
Future mechanistic studies are needed to further elucidate these important findings. 
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TABLE 1. Group characteristics 
 
   Insulin Sensitive  Insulin Resistant 
n 10 12 
Age, yr 64.5 ± 1.4 66.7 ± 0.82 
Body mass, kg 81.1 ± 3.0 81.7 ± 2.5 
BMI, kg/m2 30.3 ± 1.1 31.3 ± 0.9 
VO2peak, ml/kgBW/min 15.8 ± 1.1 15.5 ± 1.0 
Fasting plasma insulin, mU/ml 3.7 ± 0.5 6.5 ± 1.3 
Fasting plasma glucose, mg/dl 94.1 ± 5.1 96.7 ± 5.0 
Fasting plasma FFA, µM 502.4 ± 41.2 543.3 ± 41.7 
OGTT Glucose @ 120min, mg/dl 122 ± 10 164 ± 12* 
Rd, ml/kgFFM/min 10.2 ± 0.3 7.1 ± 0.4* 
 
Data are means ± SEM. BW, body weight. FFM, fat free mass. FFA, free fatty acid. * = 
Significantly different from IS group, P < 0.05 
 
 
 
 
 
 
 
 
 
 
TABLE 2. Muscle fiber type distribution and surface area in vastus lateralis muscle 
  
Insulin Sensitive 
Group 
Insulin Resistant 
Group 
Type I myocyte content, % 59±3.9 41±2.5* 
Type II myocyte total content, % 40.5±3.9 58±2.9* 
**Type IIa myocyte content, % 24±2.7 34±1.9* 
**Type IIx myocyte content, % 14±2.5 25±3.4* 
Type I myocyte average area, µm2 5732±317 5104±417 
Type II myocyte average area, µm2 4217±348 4027±375 
 
Data are means ± SEM. * = Significantly different from IS group, P < 0.05.  
** = Data generated from analysis of subgroup, (IR, n=10; IS, n=5) 
 
 
 
 
 
 
 
 
 
TABLE 3. Correlation of Rate of Glucose Disposal (ml/kgFFM/min) with other study variables 
when data from both IR and IS groups were combined. 
  Pearson Correlation Coefficient 
Type I Myocyte content, % ** 0.608 
Type II Myocyte total content, % **-0.724 
Total Ceramide, pMol/mg protein **-0.563 
Total Saturated Ceramide, pMol/mg protein **-0.567 
Total Unsaturated Ceramide, pMol/mg protein *-0.438 
Total Diacyglyceride, pMol/mg protein 0.006 
ADRP gene expression, 2-∆Ct ** 0.810 
 
* = Correlation is significant at the level P < 0.05 
** = Correlation is significant at the level P < 0.01 
 
FIGURE 1: Sphingolipid (Panel A) and diacylglycerol (Panel B) content in vastus lateralis of IR 
and IS subjects. IR data is expressed relative to IS group, which was set to a value of 1. * = 
Significantly different from IS group, P < 0.05. 
 
FIGURE 2: Myocyte-specific IMTG content in vastus lateralis of IR and IS groups. Panel A; 
representative image of Oil red O stain (20x objective). Panel B; representative image of 
immunostain for fiber type (20x objective). Panel C; Pearson correlation of Rd with type I 
myocyte-specific IMTG content. White data points = IS subjects, Black data points = IR 
subjects. Panel D; Pearson correlation of Rd with type II myocyte-specific IMTG content. White 
data points = insulin sensitive, Black data points = insulin resistant. Panel E; IMTG content in 
type I myocytes, type II myocytes, and total IMTG in vastus lateralis from IR and IS groups. * = 
Significantly different from IS, P < 0.05. 
 
FIGURE 3: Gene expression in vastus lateralis of IR and IS sub-groups. IR gene expression is 
expressed relative to IS group, which was set to a value of 1. Black bar = IS group. White bar = 
IR group. TNF, Tumor necrosis factor. PGC, Peroxisome proliferator-activated receptor gamma 
coactivator. PPAR, Peroxisome proliferator-activated receptor. NRF, Nuclear respiratory factor. 
ACAC, Acetyl-Coenzyme A carboxylase. MLYCD, Malonyl-CoA decarboxylase. CPT, 
Carnitine palmitoyltransferase. SNAP, Synaptosomal-associated protein. ATGL, Adipose 
triglyceride lipase. ADRP, Adipose differentiation-related protein. HSL, Hormone sensitive 
lipase. S3-12, Plasma membrane associated protein KIAA1881. CERK, Ceramide kinase. 
ASAH, N-acylsphingosine amidohydrolase. SPTLC, Serine palmitoyltransferase, long chain 
base. ABHD5, Abhydrolase domain containing 5. GLUT4, Facilitated glucose transporter 
member 4. IRS, insulin receptor substrate. * = Significantly different from IS group, P < 0.05. 
 
 
 



